[go: up one dir, main page]

BR9814592A - "compostos azopolicìclicos condensados com arila" - Google Patents

"compostos azopolicìclicos condensados com arila"

Info

Publication number
BR9814592A
BR9814592A BR9814592-4A BR9814592A BR9814592A BR 9814592 A BR9814592 A BR 9814592A BR 9814592 A BR9814592 A BR 9814592A BR 9814592 A BR9814592 A BR 9814592A
Authority
BR
Brazil
Prior art keywords
compounds
azopolycyclic
aryl
compounds condensed
condensed
Prior art date
Application number
BR9814592-4A
Other languages
English (en)
Other versions
BR9814592B1 (pt
Inventor
Jotham Wadsworth Coe
Paige Roanne Palmer Brooks
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9814592(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9814592A publication Critical patent/BR9814592A/pt
Publication of BR9814592B1 publication Critical patent/BR9814592B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS AZAPOLICìCLICOS CONDENSADOS COM ARILA"<D>. São reivindicados compostos da fórmula e seus sais farmaceuticamente aceitáveis, em que R¹, R², R³ e n são como definidos na especificação, intermediários na síntese de tais compostos, composições farmacêuticas contendo tais compostos e métodos de utilização de tais compostos no tratamento de distúrbios neurológicas e psicológicas.
BRPI9814592-4A 1997-12-31 1998-11-13 composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento. BR9814592B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7024597P 1997-12-31 1997-12-31
PCT/IB1998/001813 WO1999035131A1 (en) 1997-12-31 1998-11-13 Aryl fused azapolycyclic compounds

Publications (2)

Publication Number Publication Date
BR9814592A true BR9814592A (pt) 2000-10-17
BR9814592B1 BR9814592B1 (pt) 2010-06-01

Family

ID=22094096

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9816186-5A BR9816186B1 (pt) 1997-12-31 1998-11-13 processo para preparar compostos azapolicÍclico condensados com arila.
BRPI9814592-4A BR9814592B1 (pt) 1997-12-31 1998-11-13 composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI9816186-5A BR9816186B1 (pt) 1997-12-31 1998-11-13 processo para preparar compostos azapolicÍclico condensados com arila.

Country Status (51)

Country Link
US (6) US6410550B1 (pt)
EP (2) EP1044189B2 (pt)
JP (1) JP3550359B2 (pt)
KR (1) KR100408138B1 (pt)
CN (2) CN1715280A (pt)
AP (1) AP1170A (pt)
AR (1) AR017967A1 (pt)
AT (1) ATE386024T1 (pt)
AU (1) AU753389C (pt)
BG (1) BG65058B1 (pt)
BR (2) BR9816186B1 (pt)
CA (1) CA2316921C (pt)
CO (1) CO4810373A1 (pt)
CY (2) CY1107391T1 (pt)
CZ (1) CZ301925B6 (pt)
DE (2) DE122008000038I1 (pt)
DK (1) DK1044189T4 (pt)
DZ (1) DZ2697A1 (pt)
EA (1) EA003190B1 (pt)
EG (1) EG23816A (pt)
ES (1) ES2301210T5 (pt)
FR (1) FR08C0039I2 (pt)
GT (2) GT199800200AA (pt)
HN (1) HN1998000177A (pt)
HR (2) HRP20050506A2 (pt)
HU (2) HU230297B1 (pt)
IL (2) IL136727A0 (pt)
IS (1) IS5514A (pt)
LU (1) LU91442I2 (pt)
MA (1) MA26589A1 (pt)
ME (1) ME00459B (pt)
MY (1) MY118163A (pt)
NL (1) NL300355I2 (pt)
NO (2) NO319115B1 (pt)
NZ (1) NZ504482A (pt)
OA (1) OA11428A (pt)
PA (1) PA8463901A1 (pt)
PE (1) PE20000053A1 (pt)
PL (1) PL209404B1 (pt)
PT (1) PT1044189E (pt)
RS (1) RS50069B (pt)
SA (1) SA99191123B1 (pt)
SG (1) SG102686A1 (pt)
SI (1) SI1044189T2 (pt)
SK (1) SK286886B6 (pt)
TN (1) TNSN98237A1 (pt)
TR (1) TR200001840T2 (pt)
TW (1) TW513412B (pt)
UA (1) UA66825C2 (pt)
WO (1) WO1999035131A1 (pt)
ZA (1) ZA9811911B (pt)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
HRP20050506A2 (en) * 1997-12-31 2006-03-31 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
AU781084B2 (en) 1999-07-28 2005-05-05 Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
RU2282619C9 (ru) * 2001-04-20 2006-12-20 Пфайзер Продактс Инк. Способы получения замещенных арилконденсированных азаполициклических соединений, промежуточные продукты и способы их получения
HRP20030911A2 (en) 2001-05-14 2004-02-29 Pfizer Prod Inc Citrate salt 5,8,14,-triazatetracyclo (10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>)-hexadeca-2 (11), 3,5,7,9-pentaene
NZ528210A (en) 2001-05-14 2005-04-29 Pfizer Prod Inc Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
CA2468705A1 (en) 2001-11-29 2003-06-05 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
KR20040063975A (ko) 2001-11-30 2004-07-15 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]-헥사데카-2(11)3,5,7,9-펜타엔의 약학 조성물
BR0214578A (pt) 2001-11-30 2004-11-03 Pfizer Prod Inc Compostos azopolicìclicos fundidos com arila
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
ES2361993T5 (es) 2002-02-14 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento con enzimas de productos alimenticios para celiaquía
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7605150B2 (en) * 2002-05-14 2009-10-20 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
ES2383595T3 (es) * 2002-11-20 2012-06-22 The Board Of Trustees Of The Leland Stanford Junior University Procedimiento de diagnóstico de la celiaquía
RS20050366A (sr) 2002-11-20 2007-12-31 Pfizer Products Inc., Postupak za dobijanje indan-1,3- dikarboksilne kiseline
KR100655848B1 (ko) * 2002-11-25 2006-12-11 화이자 프로덕츠 인크. 1,3-치환된 인덴의 개선된 제조 방법
MXPA05007565A (es) * 2003-01-15 2005-09-21 Pfizer Prod Inc Procedimiento mejorado de preparacion de lactamas policiclicas fusionadas con arilos.
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
JP2006528237A (ja) * 2003-05-20 2006-12-14 ファイザー・プロダクツ・インク バレニクリンの医薬組成物
PT1638971E (pt) * 2003-06-04 2008-10-23 Pfizer Prod Inc Preparação de quinoxalinas substituídas a partir da dianilina com 2,3-di-hidroxi-1,4-dioxano
WO2005007655A1 (en) 2003-07-21 2005-01-27 Pfizer Products Inc. Nicotine addiction reducing heteroaryl fused azapolycyclic compounds
CA2533100A1 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
US7766018B2 (en) 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
MX2007010375A (es) * 2005-02-24 2007-09-25 Pfizer Prod Inc Preparacion de quinoxalina sustituida de elevada pureza.
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
AU2007231072A1 (en) * 2006-03-27 2007-10-04 Pfizer Products Inc. Varenicline standards and impurity controls
BRPI0710914A2 (pt) * 2006-04-24 2011-09-27 Pfizer Prod Inc forma de dosagem e método para o tratamento de dependência, adição e supressão de nicotina, em particular para uso na terapia para parar de fumar
EP2255848A3 (en) 2006-09-04 2011-04-06 NeuroSearch AS Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
RU2009116260A (ru) * 2006-11-09 2010-11-10 Пфайзер Продактс Инк. (Us) Полиморфные модификации никотиновых промежуточных продуктов
CA2680590C (en) * 2007-03-16 2017-10-17 Jonathan David Gass Combination enzyme therapy for digestion of dietary gluten
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
EP2260037A2 (en) * 2008-02-15 2010-12-15 Medichem, S.A. A polymorphic form of a pyrazino [2,3-h] [3] benzazepine derivative
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
WO2009146031A1 (en) 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
EP2268639A2 (en) * 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
EP2204369A1 (en) 2008-12-22 2010-07-07 Medichem, S.A. Process for preparing varenicline and intermediates for use therein
US8063032B2 (en) 2009-02-11 2011-11-22 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
CA2801842A1 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
WO2010151524A1 (en) 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
MX2012002827A (es) * 2009-09-11 2012-04-10 Sunovion Pharmaceuticals Inc Agonistas inversos y antagonistas de histamina h3 y metodos para usar los mismos.
EP2545054A1 (en) 2010-03-09 2013-01-16 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
KR101109389B1 (ko) * 2010-04-30 2012-01-30 삼성전기주식회사 인쇄회로기판 및 그 제조방법
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
CA2840480A1 (en) 2011-06-30 2013-01-03 Toray Industries, Inc. Antipruritic agent
ITMI20111413A1 (it) 2011-07-28 2013-01-29 Dipharma Francis Srl Procedimento per la preparazione di vareniclina
ES2426838B1 (es) 2012-04-20 2014-05-07 Genetracer Biotech S.L Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico
ES2426517B1 (es) 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
CN103570502A (zh) * 2012-07-18 2014-02-12 上海科胜药物研发有限公司 一种伐伦克林中间体的制备方法
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN103992272B (zh) * 2014-06-09 2016-05-11 安徽省逸欣铭医药科技有限公司 一种盐酸喷他佐辛酯、其制备方法及其用途
KR20160126697A (ko) 2015-04-24 2016-11-02 한미정밀화학주식회사 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20160143407A (ko) 2015-06-05 2016-12-14 한미정밀화학주식회사 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
CN106674194B (zh) * 2016-12-14 2019-03-05 山东省联合农药工业有限公司 一种结构新颖的烟碱类杀虫剂及其制备方法和用途
CN110381919A (zh) 2017-03-03 2019-10-25 西梯茜生命工学股份有限公司 含有伐尼克兰或其药学上可接受的盐的包合复合物的口服施用制剂
KR102463733B1 (ko) 2017-06-30 2022-11-04 한미약품 주식회사 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
WO2021222230A1 (en) 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
WO2022035434A1 (en) 2020-08-14 2022-02-17 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
US11040983B1 (en) 2020-08-14 2021-06-22 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (en) * 2020-12-30 2022-07-07 Antares Pharma, Inc. Varenicline prodrugs
WO2022222019A1 (en) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Total synthesis of varenicline
CN113277993B (zh) * 2021-06-06 2023-07-21 湖南第一师范学院 一种Tafamidis及其衍生物的合成方法
WO2023275413A2 (en) 2021-12-23 2023-01-05 Medichem, S.A. Solid pharmaceutical formulations of varenicline
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
US12018009B2 (en) 2022-06-14 2024-06-25 Amygdala Neurosciences, Inc. ALDH-2 inhibitor compounds and methods of use
EP4611896A1 (en) 2022-11-04 2025-09-10 Pfizer Inc. Prodrugs of varenicline and compounds containing vulnerable amines
IT202300003888A1 (it) 2023-03-03 2024-09-03 Dipharma Francis Srl Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina
WO2024224270A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Varenicline formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) * 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
JPH11512443A (ja) † 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
HRP20050506A2 (en) * 1997-12-31 2006-03-31 Pfizer Products Inc. Aryl fused azapolycyclic compounds
WO1999042461A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
KR100420423B1 (ko) * 1998-04-29 2004-03-04 화이자 프로덕츠 인코포레이티드 아릴 축합된 아자 다환식 화합물
IL144340A0 (en) * 1999-01-29 2002-05-23 Abbott Lab Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
NZ528210A (en) * 2001-05-14 2005-04-29 Pfizer Prod Inc Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
HRP20030911A2 (en) * 2001-05-14 2004-02-29 Pfizer Prod Inc Citrate salt 5,8,14,-triazatetracyclo (10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>)-hexadeca-2 (11), 3,5,7,9-pentaene
CA2468705A1 (en) * 2001-11-29 2003-06-05 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
KR20040063975A (ko) * 2001-11-30 2004-07-15 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]-헥사데카-2(11)3,5,7,9-펜타엔의 약학 조성물
BR0214578A (pt) * 2001-11-30 2004-11-03 Pfizer Prod Inc Compostos azopolicìclicos fundidos com arila
CA2533100A1 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds

Also Published As

Publication number Publication date
US20020072524A1 (en) 2002-06-13
LU91442I9 (pt) 2018-12-31
AP9801422A0 (en) 1998-12-31
DK1044189T3 (da) 2008-05-13
AR017967A1 (es) 2001-10-24
AU9641698A (en) 1999-07-26
NO319115B1 (no) 2005-06-20
DK1044189T4 (en) 2015-03-30
UA66825C2 (uk) 2004-06-15
LU91442I2 (fr) 2008-07-21
TR200001840T2 (tr) 2000-12-21
PE20000053A1 (es) 2000-02-07
WO1999035131A1 (en) 1999-07-15
SG102686A1 (en) 2004-03-26
JP2002500218A (ja) 2002-01-08
IL136727A0 (en) 2001-06-14
DE69839131T3 (de) 2015-05-07
JP3550359B2 (ja) 2004-08-04
HRP20000445B1 (hr) 2009-04-30
CA2316921A1 (en) 1999-07-15
KR100408138B1 (ko) 2003-12-01
CO4810373A1 (es) 1999-06-30
BR9816186B1 (pt) 2009-01-13
HUP0100949A2 (hu) 2001-08-28
MY118163A (en) 2004-09-30
HUS1600018I1 (hu) 2018-05-02
CY2008013I2 (el) 2009-11-04
NZ504482A (en) 2003-01-31
CZ20002438A3 (cs) 2002-11-13
CA2316921C (en) 2004-12-07
KR20010033823A (ko) 2001-04-25
RS50069B (sr) 2009-01-22
DE69839131D1 (de) 2008-03-27
NO2006016I1 (no) 2006-11-27
SK9712000A3 (en) 2002-03-05
GT199800200AA (es) 2000-06-07
EP1044189B2 (en) 2015-02-25
NO2006016I2 (pt) 2008-10-20
ZA9811911B (en) 2000-06-29
EA200000592A1 (ru) 2000-12-25
EP1044189B1 (en) 2008-02-13
CY1107391T1 (el) 2010-07-28
ES2301210T3 (es) 2008-06-16
ES2301210T5 (es) 2015-05-07
EP1044189A1 (en) 2000-10-18
TNSN98237A1 (fr) 2005-03-15
DZ2697A1 (fr) 2003-03-29
OA11428A (en) 2004-05-03
AU753389C (en) 2007-08-09
ME00459B (me) 2011-10-10
PA8463901A1 (es) 2000-09-29
PL341824A1 (en) 2001-05-07
PL209404B1 (pl) 2011-08-31
HN1998000177A (es) 1999-02-09
NO20003422L (no) 2000-08-29
HU230297B1 (hu) 2015-12-28
BR9814592B1 (pt) 2010-06-01
SK286886B6 (sk) 2009-07-06
HUP0100949A3 (en) 2002-12-28
BG65058B1 (bg) 2007-01-31
US20020132824A1 (en) 2002-09-19
SA99191123B1 (ar) 2006-10-02
CY2008013I1 (el) 2009-11-04
HRP20050506A2 (en) 2006-03-31
US6410550B1 (en) 2002-06-25
EG23816A (en) 2007-09-19
CN1285821A (zh) 2001-02-28
DE122008000038I1 (de) 2008-11-13
AP1170A (en) 2003-06-30
EP1659114A2 (en) 2006-05-24
IL136727A (en) 2006-06-11
HK1031878A1 (en) 2001-06-29
PT1044189E (pt) 2008-04-22
CN1324013C (zh) 2007-07-04
YU40300A (sh) 2003-10-31
US6951938B2 (en) 2005-10-04
NL300355I1 (nl) 2008-08-01
CZ301925B6 (cs) 2010-08-04
BG104561A (en) 2001-01-31
TW513412B (en) 2002-12-11
EA003190B1 (ru) 2003-02-27
SI1044189T2 (sl) 2015-05-29
MA26589A1 (fr) 2004-12-20
EP1659114A3 (en) 2007-01-17
AU753389B2 (en) 2002-10-17
HRP20000445A2 (en) 2001-04-30
US6887884B2 (en) 2005-05-03
NO20003422D0 (no) 2000-06-30
FR08C0039I1 (pt) 2008-11-14
NL300355I2 (nl) 2008-11-03
CN1715280A (zh) 2006-01-04
DE69839131T2 (de) 2009-02-05
US20020072525A1 (en) 2002-06-13
SI1044189T1 (sl) 2008-06-30
IS5514A (is) 2000-05-26
ATE386024T1 (de) 2008-03-15
FR08C0039I2 (fr) 2009-12-18
GT199800200A (es) 2000-06-07
US6897310B2 (en) 2005-05-24
US20070275973A1 (en) 2007-11-29
US20020111350A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
BR9814592A (pt) &#34;compostos azopolicìclicos condensados com arila&#34;
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
BR9913512A (pt) Derivados de 4,4-biarilpiperidina com atividade de receptor de opióide
BR9713552A (pt) Derivados de pirimidina bicìclicos condensados
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
BR0014178A (pt) Derivados de ácido dicarboxìlico com propriedades farmacêuticas
BRPI0001486B8 (pt) processos e intermediários para preparar compostos anticancerígenos
BR9810021A (pt) Derivados 9-oxima-eritromicina
AP9701041A0 (en) Pyridylpyrrole compounds.
BR9914998A (pt) Antibióticos macrólidos
BR9910058A (pt) Compostos azapolicìclicos aril-condensados
BR9811093A (pt) Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
BR9916680A (pt) Derivados da 3,3-biarilpiperidina e2,2-biarilmorfolina
BR0013781A (pt) Pirazolo [4,3-d]pirimidinas
BR9910032A (pt) Tienopirimidinas
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
BR9812443A (pt) 1-2-3-4-5-6-hexahidro-2,6-metano-3-benzazocin-10-óis substituìdos, processos para sua preparação e seu emprego como medicamentos
BR9910206A (pt) Derivados de higromicina a.
BR0211025A (pt) Um novo composto para o tratamento da impotência
BR0000901A (pt) Derivados 4-fenil-4-heteroarilpiperidina
BR9902347A (pt) Azabiciclos como inibidores de rotomase
BRPI0412880A (pt) compostos azapolicìclicos fundidos a arila
BR0012329A (pt) Derivados de benzofurano
FR2766487B1 (fr) Thiazolobenzoheterocycles, leur preparation et les medicaments les contenant

Legal Events

Date Code Title Description
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: C07D 221/26, C07D 471/08, C07D 498/08, C07D 513/08, A61K 31/55, A61P 1/00, A61P 29/00, A61P 25/00, A61P 25/24, A61P 25/28, A61P 25/32, A61P 25/34, A61P 25/36, A61P 25/14, A61P 9/12, A61P 3/04, A61P 9/06, A61P 1/04, A61P 25/06, A61P 25/08, A61P 25/16

Ipc: C07D 221/26 (2007.01), C07D 471/08 (2007.01), C07D

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/06/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/06/2020.